Spun out of Tübingen, Justus Liebig University Gießen and Münster, Atriva Therapeutics has raised an initial $1.4m to progress next-generation antiviral drugs for conditions including influenza.

Atriva Therapeutics, a Germany-based antiviral therapy spinout from the universities of Tübingen, Justus Liebig Gießen and Münster, has raised €1.3m ($1.4m) in an initial series A tranche co-led by public-private partnership High-Tech Gründerfonds and investment firm Meneldor.
The round also features unnamed members of Atriva’s founding and management team.
Founded in 2015, Atriva is working on next-generation antiviral drugs to combat respiratory viral infections such as influenza, in the hope of counteracting flu strains that are becoming progressively…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?